ArticleCurrent microbiology2026
Inhibitory Effects of Oxysterlina 3, Satanin 1, and Curvicin Cecropins on the Growth and stx2 Gene Expression of Shiga Toxin-Producing Escherichia coli (STEC).
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Shiga toxin-producing Escherichia coli (STEC) poses a significant health risk, with Stx1 and Stx2 as key virulence factors associated with hemolytic uremic syndrome (HUS). Current STEC treatment relies on supportive care, avoiding antimicrobial therapy. This study evaluates the antibacterial activity of three cecropin peptides and their effect on the expression of the stx2 gene in STEC. Employing microdilution assays and RT-qPCR, all three cecropins demonstrated antibacterial efficacy, displaying MIC and MBC values of 12.5 µg/mL, and decreased gene expression levels following treatment. Notably, these cecropins not only inhibited STEC growth but also significantly reduced stx2 mRNA expression. These findings underscore the therapeutic potential of cecropins as an alternative treatment for STEC infections and suggest they may mitigate associated complications.
Indexed as
Identifiers
42645551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.